Novartis AG (NVS)
22 Aug 2014
|Market Cap (Mil.):||$241,550.09|
|Shares Outstanding (Mil.):||2,706.19|
- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.
(Adds details on drug, rival drugs, new treatment approach)
Aug 20 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:
ZURICH - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.
* Novartis move adds to Big Pharma retreat from antibiotics R&D (Adds detail, analyst, Novartis comment)
ZURICH, Aug 20 - Novartis said on Wednesday it had signed an a deal to exclusively license its experimental drugs for tuberculosis (TB) to the Global Alliance for TB Drug Development.
JERUSALEM - Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.
JERUSALEM, Aug 19 - Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.
Aug 11 - Novartis AG : * Says to showcase heart failure leadership at ESC congress 2014 with
NEW YORK - A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.
|Johnson & Johnson (JNJ.N)||$103.10||-0.39|
|Pfizer Inc. (PFE.N)||$28.92||+0.10|
|Merck & Co., Inc. (MRK.N)||$59.17||+0.32|
|Roche Holding Ltd. (ROG.VX)||CHF265.90||+0.10|
|Abbott Laboratories (ABT.N)||$42.11||-0.21|
|Sanofi SA (SASY.PA)||€79.43||-1.16|
|AstraZeneca plc (AZN.L)||4,418.00p||+6.50|
|GlaxoSmithKline plc (GSK.L)||1,429.50p||-5.00|
|Eli Lilly and Co (LLY.N)||$62.32||+0.29|
|Bristol-Myers Squibb Co (BMY.N)||$50.18||+0.19|
Earnings vs. Estimates
Analyst Research Reports
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
Provider: Stock Traders Daily
Novartis AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
"The Economy Matters" Report for NVS: the economy's impact on NVS's price and risk, featuring the powerful Economic Climate Rating
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.